Purchase this article with an account.
Matthew S J Katz, Solly Elmann, Natsumi Takahashi, Bert M Glaser; In-Office Vitreous Proteomics Suggests Role of TGFβ in the Fibrovascular Component of CNV in Eyes with Wet AMD. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5777.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Wet Age-related Macular Degeneration is accompanied by remodeling of the choroidal interstitial stroma including Bruch’s Membrane characterized by serous, hemorrhagic, and fibrovascular pigment epithelium detachments (PEDs) among the varied manifestations. TGFβ has been found to be a factor in the process of interstitial stromal remodeling in a wide variety of settings. To help elucidate the biochemical pathways that drive these interstitial changes in wet AMD, we studied the levels of TGFβ in sequential vitreous samples obtained in-office before and after treatments resulting in improvement of these interstitial stromal changes of the choroid.
Sequential vitreous aspirates (50-150μL) were obtained from 20 eyes of 19 patients treated for wet AMD with intravitreal injection of bevacizumab between 12/1/07 and 11/1/13 in an IRB approved study. During the course of treatment, these eyes had interstitial stromal pathology of the choroid that prompted Feeder Vessel Treatment (FVTx) resulting in rapid reduction of PEDs and other interstitial changes. All vitreous samples were investigated utilizing RPPM (Reverse Phase Protein Microarray) technology. TGFβ levels were measured in Relative Intensity Units and fold changes were calculated.
TGFβ levels were observed to increase by 21% from pretreatment levels in samples collected 1-4 weeks following FVTx. TGFβ levels were observed to increase by 53.7% from pretreatment levels in samples collected 5-10 weeks following FVTx.
In-office vitreous sampling reveals a progressive increase in TGFβ levels correlating with morphologic resolution of the choroidal interstitial changes. In neoplasia, TGFβ has been demonstrated to inhibit early angiogenesis and to suppress tumor growth. However, this biomolecule’s activity has been found to be to differ across different tissues and different physiologic conditions. These findings may assist in our understanding of the biochemical pathways that drive pathologic interstitial choroidal changes in wet AMD.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only